Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Denis Horgan [verfasserIn] Gennaro Ciliberto [verfasserIn] Pierfranco Conte [verfasserIn] Giuseppe Curigliano [verfasserIn] Luis Seijo [verfasserIn] Luis M. Montuenga [verfasserIn] Marina Garassino [verfasserIn] Frederique Penault-Llorca [verfasserIn] Fabrizia Galli [verfasserIn] Isabelle Ray-Coquard [verfasserIn] Denis Querleu [verfasserIn] Peter Riegman [verfasserIn] Keith Kerr [verfasserIn] Hein Van Poppel [verfasserIn] Anders Bjartell [verfasserIn] Giovanni Codacci-Pisanelli [verfasserIn] Jasmina Koeva-Balabanova [verfasserIn] Angelo Paradiso [verfasserIn] Zorana Maravic [verfasserIn] Vassiliki Fotaki [verfasserIn] Nuria Malats [verfasserIn] Chiara Bernini [verfasserIn] Simonetta Buglioni [verfasserIn] Alastair Kent [verfasserIn] Elisabetta Munzone [verfasserIn] Ivica Belina [verfasserIn] Jan Van Meerbeeck [verfasserIn] Michael Duffy [verfasserIn] Beata Jagielska [verfasserIn] Ettore Capoluongo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Cancers - MDPI AG, 2010, 13(2021), 3, p 583 |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2021 ; number:3, p 583 |
| Links: |
|---|
| DOI / URN: |
10.3390/cancers13030583 |
|---|
| Katalog-ID: |
DOAJ047817569 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ047817569 | ||
| 003 | DE-627 | ||
| 005 | 20240414083643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13030583 |2 doi | |
| 035 | |a (DE-627)DOAJ047817569 | ||
| 035 | |a (DE-599)DOAJ74b76549363c4c63953a57c663011df2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Denis Horgan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. | ||
| 650 | 4 | |a Europe’s Healthcare Systems | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a oncogenomics | |
| 650 | 4 | |a HRD | |
| 650 | 4 | |a cancers | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Gennaro Ciliberto |e verfasserin |4 aut | |
| 700 | 0 | |a Pierfranco Conte |e verfasserin |4 aut | |
| 700 | 0 | |a Giuseppe Curigliano |e verfasserin |4 aut | |
| 700 | 0 | |a Luis Seijo |e verfasserin |4 aut | |
| 700 | 0 | |a Luis M. Montuenga |e verfasserin |4 aut | |
| 700 | 0 | |a Marina Garassino |e verfasserin |4 aut | |
| 700 | 0 | |a Frederique Penault-Llorca |e verfasserin |4 aut | |
| 700 | 0 | |a Fabrizia Galli |e verfasserin |4 aut | |
| 700 | 0 | |a Isabelle Ray-Coquard |e verfasserin |4 aut | |
| 700 | 0 | |a Denis Querleu |e verfasserin |4 aut | |
| 700 | 0 | |a Peter Riegman |e verfasserin |4 aut | |
| 700 | 0 | |a Keith Kerr |e verfasserin |4 aut | |
| 700 | 0 | |a Hein Van Poppel |e verfasserin |4 aut | |
| 700 | 0 | |a Anders Bjartell |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanni Codacci-Pisanelli |e verfasserin |4 aut | |
| 700 | 0 | |a Jasmina Koeva-Balabanova |e verfasserin |4 aut | |
| 700 | 0 | |a Angelo Paradiso |e verfasserin |4 aut | |
| 700 | 0 | |a Zorana Maravic |e verfasserin |4 aut | |
| 700 | 0 | |a Vassiliki Fotaki |e verfasserin |4 aut | |
| 700 | 0 | |a Nuria Malats |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Bernini |e verfasserin |4 aut | |
| 700 | 0 | |a Simonetta Buglioni |e verfasserin |4 aut | |
| 700 | 0 | |a Alastair Kent |e verfasserin |4 aut | |
| 700 | 0 | |a Elisabetta Munzone |e verfasserin |4 aut | |
| 700 | 0 | |a Ivica Belina |e verfasserin |4 aut | |
| 700 | 0 | |a Jan Van Meerbeeck |e verfasserin |4 aut | |
| 700 | 0 | |a Michael Duffy |e verfasserin |4 aut | |
| 700 | 0 | |a Beata Jagielska |e verfasserin |4 aut | |
| 700 | 0 | |a Ettore Capoluongo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Cancers |d MDPI AG, 2010 |g 13(2021), 3, p 583 |w (DE-627)614095670 |w (DE-600)2527080-1 |x 20726694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:3, p 583 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13030583 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/74b76549363c4c63953a57c663011df2 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/3/583 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-6694 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 3, p 583 | ||
| author_variant |
d h dh g c gc p c pc g c gc l s ls l m m lmm m g mg f p l fpl f g fg i r c irc d q dq p r pr k k kk h v p hvp a b ab g c p gcp j k b jkb a p ap z m zm v f vf n m nm c b cb s b sb a k ak e m em i b ib j v m jvm m d md b j bj e c ec |
|---|---|
| matchkey_str |
article:20726694:2021----::rnignonoainouoehatcrsseshptnilfimretsigeloleiectmuansi |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
RC |
| publishDate |
2021 |
| allfields |
10.3390/cancers13030583 doi (DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 DE-627 ger DE-627 rakwb eng RC254-282 Denis Horgan verfasserin aut Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut Giuseppe Curigliano verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Angelo Paradiso verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Nuria Malats verfasserin aut Chiara Bernini verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Beata Jagielska verfasserin aut Ettore Capoluongo verfasserin aut In Cancers MDPI AG, 2010 13(2021), 3, p 583 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:3, p 583 https://doi.org/10.3390/cancers13030583 kostenfrei https://doaj.org/article/74b76549363c4c63953a57c663011df2 kostenfrei https://www.mdpi.com/2072-6694/13/3/583 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 3, p 583 |
| spelling |
10.3390/cancers13030583 doi (DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 DE-627 ger DE-627 rakwb eng RC254-282 Denis Horgan verfasserin aut Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut Giuseppe Curigliano verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Angelo Paradiso verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Nuria Malats verfasserin aut Chiara Bernini verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Beata Jagielska verfasserin aut Ettore Capoluongo verfasserin aut In Cancers MDPI AG, 2010 13(2021), 3, p 583 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:3, p 583 https://doi.org/10.3390/cancers13030583 kostenfrei https://doaj.org/article/74b76549363c4c63953a57c663011df2 kostenfrei https://www.mdpi.com/2072-6694/13/3/583 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 3, p 583 |
| allfields_unstemmed |
10.3390/cancers13030583 doi (DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 DE-627 ger DE-627 rakwb eng RC254-282 Denis Horgan verfasserin aut Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut Giuseppe Curigliano verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Angelo Paradiso verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Nuria Malats verfasserin aut Chiara Bernini verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Beata Jagielska verfasserin aut Ettore Capoluongo verfasserin aut In Cancers MDPI AG, 2010 13(2021), 3, p 583 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:3, p 583 https://doi.org/10.3390/cancers13030583 kostenfrei https://doaj.org/article/74b76549363c4c63953a57c663011df2 kostenfrei https://www.mdpi.com/2072-6694/13/3/583 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 3, p 583 |
| allfieldsGer |
10.3390/cancers13030583 doi (DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 DE-627 ger DE-627 rakwb eng RC254-282 Denis Horgan verfasserin aut Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut Giuseppe Curigliano verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Angelo Paradiso verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Nuria Malats verfasserin aut Chiara Bernini verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Beata Jagielska verfasserin aut Ettore Capoluongo verfasserin aut In Cancers MDPI AG, 2010 13(2021), 3, p 583 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:3, p 583 https://doi.org/10.3390/cancers13030583 kostenfrei https://doaj.org/article/74b76549363c4c63953a57c663011df2 kostenfrei https://www.mdpi.com/2072-6694/13/3/583 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 3, p 583 |
| allfieldsSound |
10.3390/cancers13030583 doi (DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 DE-627 ger DE-627 rakwb eng RC254-282 Denis Horgan verfasserin aut Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut Giuseppe Curigliano verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Angelo Paradiso verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Nuria Malats verfasserin aut Chiara Bernini verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Beata Jagielska verfasserin aut Ettore Capoluongo verfasserin aut In Cancers MDPI AG, 2010 13(2021), 3, p 583 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:3, p 583 https://doi.org/10.3390/cancers13030583 kostenfrei https://doaj.org/article/74b76549363c4c63953a57c663011df2 kostenfrei https://www.mdpi.com/2072-6694/13/3/583 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 3, p 583 |
| language |
English |
| source |
In Cancers 13(2021), 3, p 583 volume:13 year:2021 number:3, p 583 |
| sourceStr |
In Cancers 13(2021), 3, p 583 volume:13 year:2021 number:3, p 583 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Cancers |
| authorswithroles_txt_mv |
Denis Horgan @@aut@@ Gennaro Ciliberto @@aut@@ Pierfranco Conte @@aut@@ Giuseppe Curigliano @@aut@@ Luis Seijo @@aut@@ Luis M. Montuenga @@aut@@ Marina Garassino @@aut@@ Frederique Penault-Llorca @@aut@@ Fabrizia Galli @@aut@@ Isabelle Ray-Coquard @@aut@@ Denis Querleu @@aut@@ Peter Riegman @@aut@@ Keith Kerr @@aut@@ Hein Van Poppel @@aut@@ Anders Bjartell @@aut@@ Giovanni Codacci-Pisanelli @@aut@@ Jasmina Koeva-Balabanova @@aut@@ Angelo Paradiso @@aut@@ Zorana Maravic @@aut@@ Vassiliki Fotaki @@aut@@ Nuria Malats @@aut@@ Chiara Bernini @@aut@@ Simonetta Buglioni @@aut@@ Alastair Kent @@aut@@ Elisabetta Munzone @@aut@@ Ivica Belina @@aut@@ Jan Van Meerbeeck @@aut@@ Michael Duffy @@aut@@ Beata Jagielska @@aut@@ Ettore Capoluongo @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
614095670 |
| id |
DOAJ047817569 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ047817569</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414083643.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers13030583</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ047817569</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ74b76549363c4c63953a57c663011df2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Denis Horgan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Europe’s Healthcare Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarkers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oncogenomics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRD</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancers</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Ciliberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Curigliano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Seijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis M. Montuenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marina Garassino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frederique Penault-Llorca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrizia Galli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabelle Ray-Coquard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Querleu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Riegman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keith Kerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hein Van Poppel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anders Bjartell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Codacci-Pisanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmina Koeva-Balabanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Paradiso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zorana Maravic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vassiliki Fotaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nuria Malats</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bernini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simonetta Buglioni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alastair Kent</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Munzone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ivica Belina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan Van Meerbeeck</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Jagielska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">13(2021), 3, p 583</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3, p 583</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers13030583</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/74b76549363c4c63953a57c663011df2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/13/3/583</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2021</subfield><subfield code="e">3, p 583</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Denis Horgan |
| spellingShingle |
Denis Horgan misc RC254-282 misc Europe’s Healthcare Systems misc biomarkers misc oncogenomics misc HRD misc cancers misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| authorStr |
Denis Horgan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)614095670 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
20726694 |
| topic_title |
RC254-282 Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine Europe’s Healthcare Systems biomarkers oncogenomics HRD cancers |
| topic |
misc RC254-282 misc Europe’s Healthcare Systems misc biomarkers misc oncogenomics misc HRD misc cancers misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc Europe’s Healthcare Systems misc biomarkers misc oncogenomics misc HRD misc cancers misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc Europe’s Healthcare Systems misc biomarkers misc oncogenomics misc HRD misc cancers misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Cancers |
| hierarchy_parent_id |
614095670 |
| hierarchy_top_title |
Cancers |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)614095670 (DE-600)2527080-1 |
| title |
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| ctrlnum |
(DE-627)DOAJ047817569 (DE-599)DOAJ74b76549363c4c63953a57c663011df2 |
| title_full |
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| author_sort |
Denis Horgan |
| journal |
Cancers |
| journalStr |
Cancers |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Denis Horgan Gennaro Ciliberto Pierfranco Conte Giuseppe Curigliano Luis Seijo Luis M. Montuenga Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Peter Riegman Keith Kerr Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Jasmina Koeva-Balabanova Angelo Paradiso Zorana Maravic Vassiliki Fotaki Nuria Malats Chiara Bernini Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Beata Jagielska Ettore Capoluongo |
| container_volume |
13 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Denis Horgan |
| doi_str_mv |
10.3390/cancers13030583 |
| author2-role |
verfasserin |
| title_sort |
bringing onco-innovation to europe’s healthcare systems: the potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine |
| callnumber |
RC254-282 |
| title_auth |
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| abstract |
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. |
| abstractGer |
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. |
| abstract_unstemmed |
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
3, p 583 |
| title_short |
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine |
| url |
https://doi.org/10.3390/cancers13030583 https://doaj.org/article/74b76549363c4c63953a57c663011df2 https://www.mdpi.com/2072-6694/13/3/583 https://doaj.org/toc/2072-6694 |
| remote_bool |
true |
| author2 |
Gennaro Ciliberto Pierfranco Conte Giuseppe Curigliano Luis Seijo Luis M. Montuenga Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Peter Riegman Keith Kerr Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Jasmina Koeva-Balabanova Angelo Paradiso Zorana Maravic Vassiliki Fotaki Nuria Malats Chiara Bernini Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Beata Jagielska Ettore Capoluongo |
| author2Str |
Gennaro Ciliberto Pierfranco Conte Giuseppe Curigliano Luis Seijo Luis M. Montuenga Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Peter Riegman Keith Kerr Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Jasmina Koeva-Balabanova Angelo Paradiso Zorana Maravic Vassiliki Fotaki Nuria Malats Chiara Bernini Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Beata Jagielska Ettore Capoluongo |
| ppnlink |
614095670 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3390/cancers13030583 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T14:19:22.171Z |
| _version_ |
1803567876978769920 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ047817569</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414083643.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers13030583</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ047817569</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ74b76549363c4c63953a57c663011df2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Denis Horgan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably <i<BRCA1/2</i< testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Europe’s Healthcare Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarkers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oncogenomics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRD</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancers</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Ciliberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Curigliano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Seijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis M. Montuenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marina Garassino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frederique Penault-Llorca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrizia Galli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabelle Ray-Coquard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Querleu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Riegman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keith Kerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hein Van Poppel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anders Bjartell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Codacci-Pisanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmina Koeva-Balabanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Paradiso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zorana Maravic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vassiliki Fotaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nuria Malats</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bernini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simonetta Buglioni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alastair Kent</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Munzone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ivica Belina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan Van Meerbeeck</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Jagielska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">13(2021), 3, p 583</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3, p 583</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers13030583</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/74b76549363c4c63953a57c663011df2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/13/3/583</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2021</subfield><subfield code="e">3, p 583</subfield></datafield></record></collection>
|
| score |
7.4002686 |